Luciana Parente Costa Seguro

Luciana Parente Costa Seguro

Auto-generated profile, based on publicly available information

Luciana Parente Costa Seguro

Rheumatology Division, Hospital das Clinicas HCFMUSP, Faculdade de Medicina, Universidade de Sao Paulo, Sao Paulo, Brazil

Research Focus & Metrics

Academic Career Length

18Years (2009-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
18 June 2024 in Advances in Rheumatology
Verified
Journal Article
Open access
PDF file
EREdgard Torres dos Reis-Neto
Edgard Torres dos Reis-Neto
LSLuciana Parente Costa Seguro
Luciana Parente Costa Seguro
ESEmilia Inoue Sato
Emilia Inoue Sato
EBEduardo Ferreira Borba
Eduardo Ferreira Borba
EKEvandro Mendes Klumb
Evandro Mendes Klumb
OMOdirlei Andre Monticielo
Odirlei Andre Monticielo
Objective: To develop the second evidence-based Brazilian Society of Rheumatology consensus for diagnosis and treatment of lupus nephritis (LN). Methods: Two methodologists and 20 rheumatologists from Lupus Comittee of Brazilian Society of Rheumatology participate in the development of this guideline. Fourteen PICO questions were defined and a systematic review was performed. Eligible randomized controlled trials were analyzed regarding complete renal remission, partial renal remission, serum creatinine, proteinuria, serum creatinine doubling, progression to end-stage renal disease, renal relapse, and severe adverse events (infections and mortality). The Grading of Recommendations Assessment, Development and Evaluation (GRADE) approach was used to develop these recommendations. Recommendations required ≥82% of agreement among the voting members and were classified as strongly in favor, weakly in favor, conditional, weakly against or strongly against a particular intervention. Other aspects of LN management (diagnosis, general principles of treatment, treatment of comorbidities and refractory cases) were evaluated through literature review and expert opinion. Results: All SLE patients should undergo creatinine and urinalysis tests to assess renal involvement. Kidney biopsy is considered the gold standard for diagnosing LN but, if it is not available or there is a contraindication to the procedure, therapeutic decisions should be based on clinical and laboratory parameters. Fourteen recommendations were developed. Target Renal response (TRR) was defined as improvement or maintenance of renal function (±10% at baseline of treatment) combined with a decrease in 24-h proteinuria or 24-h UPCR of 25% at 3 months, a decrease of 50% at 6 months, and proteinuria < 0.8 g/24 h at 12 months. Hydroxychloroquine should be prescribed to all SLE patients, except in cases of contraindication. Glucocorticoids should be used at the lowest dose and for the minimal necessary period. In class III or IV (±V), mycophenolate (MMF), cyclophosphamide, MMF plus tacrolimus (TAC), MMF plus belimumab or TAC can be used as induction therapy. For maintenance therapy, MMF or azathioprine (AZA) are the first choice and TAC or cyclosporin or leflunomide can be used in patients who cannot use MMF or AZA. Rituximab can be prescribed in cases of refractory disease. In cases of failure in achieving TRR, it is important to assess adherence, immunosuppressant dosage, adjuvant therapy, comorbidities, and consider biopsy/rebiopsy. Conclusion: This consensus provides evidence-based data to guide LN diagnosis and treatment, supporting the development of public and supplementary health policies in Brazil.

20 May 2022 in Lupus
Verified
Journal Article
Open access
FSFlavio Signorelli
Flavio Signorelli
GBGustavo Guimarães Moreira Balbi
Gustavo Guimarães Moreira Balbi
NANadia E Aikawa
Nadia E Aikawa
CSClovis A Silva
Clovis A Silva
LKLéonard de Vinci Kanda Kupa
Léonard de Vinci Kanda Kupa
EBEloisa Bonfá
Eloisa Bonfá
Objective: Coronavirus disease 19 (COVID-19) has an increased risk of coagulopathy with high frequency of antiphospholipid antibodies (aPL). Recent reports of thrombosis associated with adenovirus-based vaccines raised concern that SARS-CoV-2 immunization in primary antiphospholipid syndrome (PAPS) patients may trigger clotting complications. Our objectives were to assess immunogenicity, safety, and aPL production in PAPS patients, after vaccinating with Sinovac-CoronaVac, an inactivated virus vaccine against COVID-19. Methods: This prospective controlled phase-4 study of PAPS patients and a control group (CG) consisted of a two-dose Sinovac-CoronaVac (D0/D28) and blood collection before vaccination (D0), at D28 and 6 weeks after second dose (D69) for immunogenicity/aPL levels. Outcomes were seroconversion (SC) rates of anti-SARS-CoV-2 S1/S2 IgG and/or neutralizing antibodies (NAb) at D28/D69 in naïve participants. Safety and aPL production were also assessed. Results: We included 44 PAPS patients (31 naïve) and 132 CG (108 naïve) with comparable age ( p=0.982) and sex ( p>0.999). At D69, both groups had high and comparable SC (83.9% vs. 93.5%, p=0.092), as well as NAb positivity (77.4% vs. 78.7%, p=0.440), and NAb-activity (64.3% vs. 60.9%, p=0.689). Thrombotic events up to 6 months or other moderate/severe side effects were not observed. PAPS patients remained with stable aPL levels throughout the study at D0 vs. D28 vs. D69: anticardiolipin (aCL) IgG ( p=0.058) and IgM ( p=0.091); anti-beta-2 glycoprotein I (aβ2GPI) IgG ( p=0.513) and IgM ( p=0.468). Conclusion: We provided novel evidence that Sinovac-CoronaVac has high immunogenicity and safety profile in PAPS. Furthermore, Sinovac-CoronaVac did not trigger thrombosis nor induced changes in aPL production.

4 March 2025 in JCR: Journal of Clinical Rheumatology
Verified
Journal Article
Closed access
LKLeonard V.K. Kupa
Leonard V.K. Kupa
AMAna Cristina Medeiros-Ribeiro
Ana Cristina Medeiros-Ribeiro
NANádia E. Aikawa
Nádia E. Aikawa
SPSandra G. Pasoto
Sandra G. Pasoto
EBEduardo F. Borba
Eduardo F. Borba
EBEloisa Bonfá
Eloisa Bonfá
Background: Patients with autoimmune rheumatic diseases (ARDs) are at an increased risk for herpes zoster (HZ). Vaccination is recommended for this population. Objective: The aim of this study was to evaluate the safety of vaccination with the recombinant zoster vaccine (Shingrix) in ARD patients, humoral immunogenicity (HI), cellular immunogenicity (CI), and the incidence of HZ. Methods: This randomized, double-blind, placebo-controlled phase 4 study involves 1180 ARD patients and a control group (CG) of 393 balanced healthy individuals, aged ≥50 years. ARD patients will be randomly assigned in a blinded manner (1:1 ratio) to 2 groups: vaccine or placebo (on days 0 and 42), administered intramuscularly. Outcomes will be assessed at baseline, 6 weeks, and 12 weeks after vaccination, including disease activity (using specific disease activity scores), HI, and CI. Adverse events will be assessed using a standardized questionnaire after each vaccine dose. Incident HZ cases will be monitored throughout the study. One year following the second dose, the persistence of HI and CI will be evaluated in both ARD patients and CG. HI and CI will be assessed using serum concentrations of anti-gE antibodies and the frequencies of gE-specific CD4+ T cells, respectively. Comparisons of anti-gE titers between ARD patients and CG at different time points will be analyzed using 2-way repeated-measures analysis of variance. Multiple regression analysis will be conducted, with a positive immune response as the dependent variable, and variables with p < 0.2 from univariate analysis as independent variables. Conclusions: This large trial addresses a critical gap by examining disease safety, efficacy, adverse effects, and immunogenicity, considering the impact of diverse therapies following recombinant zoster vaccine administration in ARD patients.


1 October 2009 in Revista Brasileira de Reumatologia
Verified
Journal Article
Open access
PDF file
LCLuciana Parente Costa
Luciana Parente Costa
DDDiogo Souza Domiciano
Diogo Souza Domiciano
RPRosa Maria Rodrigues Pereira
Rosa Maria Rodrigues Pereira
A febre reumática (FR) se caracteriza por um processo inflamatório não supurativo que se instala após uma infecção pelo estreptococo beta-hemolítico do grupo A de Lancefield. Sua prevalência é maior nos países em desenvolvimento como o Brasil. Em nosso país, entretanto, dados epidemiológicos sistemáticos sobre a doença são incompletos e escassos. Estima-se uma prevalência de FR ao redor de 3% entre as crianças e os adolescentes brasileiros. Neste artigo, foi realizada uma revisão sistemática dos principais estudos brasileiros, utilizando como fonte de pesquisa as bases de dados do LILACS, Scielo e Medline, tendo como palavras-chave Febre Reumática e Rheumatic Fever. Foram selecionados 10 trabalhos epidemiológicos e a análise comparativa não demonstrou diferenças em relação a predominância de sexo, quadro clínico, laboratorial e radiológico dos pacientes nas diversas regiões do país.

1 January 2021
Verified
Conference Paper
Open access
GBGuilherme Guimarães Moreira Balbi
Guilherme Guimarães Moreira Balbi
CSCarla Baleeiro Rodrigues Silva
Carla Baleeiro Rodrigues Silva
NNNestor José de Souza Barreto Neto
Nestor José de Souza Barreto Neto
PFPablo Vinícius da Fonseca
Pablo Vinícius da Fonseca
ADAline Carolina Capellato Dias
Aline Carolina Capellato Dias
SSSamuel Katsuyuki Shinjo
Samuel Katsuyuki Shinjo